弥漫性大B细胞淋巴瘤综述
弥漫性大B细胞淋巴瘤约占非霍奇金淋巴瘤的30%,全球每年新发约15万例。多数患者就诊时已处晚期,但超过60%可通过R-CHOP免疫化疗治愈;一线治疗失败者预后较差,尤其难治性患者。近二十年对流行病学、预后因素及生物学异质性的认识推动了疾病分类细化和新疗法开发。
要点
- R-CHOP是弥漫性大B细胞淋巴瘤的一线标准免疫化疗方案。
- 超过60%的患者可通过R-CHOP获得治愈。
- 一线治疗失败或难治性患者预后较差,但部分仍可通过后续治疗获得持久缓解。
核心结论
- 弥漫性大B细胞淋巴瘤患者多数就诊时已为晚期,但超过60%可通过R-CHOP免疫化疗治愈。
- 一线治疗失败者预后较差,尤其难治性患者,但部分患者经后续治疗仍可获得持久缓解并治愈。
研究设计与样本
- 本文为综述,未报告系统检索策略或样本量。
主要发现
- 全球每年新发约15万例弥漫性大B细胞淋巴瘤,约占非霍奇金淋巴瘤的30%。
- 患者通常表现为进行性淋巴结肿大和/或结外病变,需要治疗。
- 超过60%的患者可通过R-CHOP免疫化疗治愈。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Large B-cell lymphomas, with an estimated 150,000 new cases annually worldwide, represent almost 30% of all cases of non-Hodgkin’s lymphoma. Patients typically present with progressive lymphadenopathy, extranodal disease, or both and require therapy. Despite the advanced stage at presentation in the majority of patients, more than 60% can be cured with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) immunochemotherapy (Fig. 1A). Patients with treatment failure after R-CHOP often have a poor outcome — in particular, those with disease that is refractory to frontline or subsequent therapies — although some patients can have a durable remission and be cured after secondary therapies. Over the past two decades, improved insights into large B-cell lymphomas, in terms of epidemiology, prognostic factors, and biologic heterogeneity, have led to a refinement of disease classification and the development of new therapeutic approaches.
引用
- Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021. PMID: 33657296. doi:10.1056/NEJMra2027612
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。